A 28-Year-Old Woman with a Positive Antibody Screen at 12 Weeks Gestation
A 28-year-old G2P1 woman at 12 weeks gestation has a routine antibody screen: positive. Her blood type is O Rh(D) negative. Her first pregnancy was uncomplicated; she received Rh immune globulin at 28 weeks and postpartum. She has no history of transfusion. The antibody screen is positive with a 1+ reaction at immediate spin and 2+ at anti-human globulin phase. The antibody identification panel shows reactivity with all panel cells, but the autocontrol is negative. Her direct antiglobulin test is negative. The blood bank is preparing for a possible intrauterine transfusion and asks for your interpretation.
1. How do you interpret the antibody screen and panel, and what is the most likely antibody? What additional testing is needed?
Read the worked answer
The positive antibody screen with a negative autocontrol indicates an alloantibody, not an autoantibody. Reactivity with all panel cells suggests a panagglutinin - most commonly anti-Rh (anti-D, anti-C, or anti-E) or anti-Kell, but a true panagglutinin reacting with all cells at AHG phase should prompt consideration of:
- Anti-D if the patient is Rh(D) negative and was sensitized (but she received RhIG; anti-D from passive RhIG can cause a positive screen for up to 6 months).
- Anti-C, anti-E, anti-K, anti-Jka, anti-Fya - but these would not react with all cells unless the panel lacks negative cells.
- A high-frequency antigen antibody (e.g., anti-U, anti-Vel, anti-Jra) - these react with all panel cells.
- Passive anti-D from RhIG - check the time since RhIG and the titer; passive anti-D usually has a low titer and weak reactivity.
Additional testing: extended phenotyping of the patient (C, c, E, e, K, Jka, Jkb, Fya, Fyb, M, N, S, s) and selected cell panels with rare phenotypes. Titer the antibody and test the father's phenotype if the antibody is clinically significant. Acid elution/adsorption may help if the autocontrol is negative but panreactivity persists.
2. The antibody is identified as anti-K (Kell). The father is K-positive. What is the risk to the fetus, and how do you manage the pregnancy?
Read the worked answer
Anti-K (Kell) is clinically significant and can cause hemolytic disease of the fetus and newborn (HDFN). Unlike anti-D, anti-K can cause severe fetal anemia at low titers because it suppresses erythropoiesis (Kell antigen is on erythroid progenitors), leading to reticulocytopenia and hyporegenerative anemia out of proportion to hemolysis. Therefore, titers are less predictive than for anti-D.
Management:
- Titer the anti-K; a titer of ≥1:8-1:16 warrants middle cerebral artery (MCA) peak systolic velocity (PSV) Doppler surveillance (usually starting at 16-18 weeks and repeated every 1-2 weeks).
- Father's genotype (K/k) determines fetal risk; if heterozygous, the fetus has a 50% chance of being K-positive. Cell-free fetal DNA (cffDNA) for K can determine fetal antigen status non-invasively.
- If MCA-PSV indicates fetal anemia, intrauterine transfusion with K-negative, crossmatch-compatible packed red cells is indicated.
- RhIG is still given at 28 weeks and postpartum because she is Rh(D) negative (anti-K does not protect against RhD sensitization).
- Postnatal: check cord blood for direct antiglobulin test, hemoglobin, bilirubin, and reticulocyte count; monitor for late anemia (hyporegenerative) and treat with transfusion if needed.
3. The blood bank must select units for a possible intrauterine transfusion. What compatibility testing is required, and what is the pitfall of using the patient's serum for crossmatch?
Read the worked answer
For intrauterine transfusion, units must be:
- K-negative (and compatible with the maternal antibody - i.e., negative for the corresponding antigen).
- Crossmatch-compatible with the maternal serum using AHG-phase crossmatch (or gel/column agglutination).
- Leukoreduced, irradiated, and CMV-safe (irradiated to prevent transfusion-associated graft-versus-host disease in the fetus/neonate; CMV-negative or leukoreduced).
- Fresh (within 5-7 days) and packed to a high hematocrit for intrauterine use.
Pitfall: The maternal serum contains the anti-K alloantibody, which will react with any K-positive unit; the crossmatch must be done with maternal serum (not fetal) and must be negative against the selected unit. If the mother has multiple alloantibodies, select units negative for all corresponding antigens. Also, do not use the fetus's serum for crossmatch because of small volume and immature immune system; maternal serum is the standard. Finally, RhIG in the mother can cause a positive crossmatch if the unit is Rh(D) positive - use Rh(D)-negative units for an Rh(D)-negative mother.